Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of five antibiotics—ampicillin, gentamicin, clindamycin, metronidazole, and ceftazidime—used together to provide extremely broad-spectrum antibacterial coverage. Each component targets different classes of bacteria or mechanisms: - Ampicillin is a beta-lactam antibiotic effective against many Gram-positive and some Gram-negative organisms. - Gentamicin is an aminoglycoside antibiotic primarily active against aerobic Gram-negative bacteria. - Clindamycin is a lincosamide antibiotic with activity against anaerobic bacteria and some Gram-positive cocci. - Metronidazole is particularly effective against anaerobic bacteria and certain protozoa by disrupting DNA synthesis. - Ceftazidime is a third-generation cephalosporin with strong activity against many Gram-negative organisms (notably Pseudomonas aeruginosa) but less so for most anaerobes[1][2][3]. This combination may be used in severe polymicrobial infections where multidrug-resistant or mixed aerobic/anaerobic pathogens are suspected.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ampicillin + gentamicin + clindamycin + metronidazole + ceftazidime.